"That pan-tumor approval and this patient case really highlight that in prostate cancer, we should be checking HER2 by immunohistochemistry," says Maneesh R. Jain, MD.

Pembrolizumab plus cisplatin-based chemotherapy showed a 43% overall response rate in small cell bladder and neuroendocrine prostate cancers. Progression-free survival at 12 months was 86% in small ...

Data from the CAPItello-281 trial also showed a trend toward an improvement in overall survival.

"There's a ton of activity in this space, and I think every 6 to 12 months, we're going to keep getting these boluses of information that's going to help us," says Gautam Jayram, MD.

Immunotherapy trials, including BCG combinations, aim to benefit BCG-naïve populations, with results expected soon. Intravesical gene therapy, such as cretostimogene, shows promise for ...

Physicians often struggle with setting boundaries due to numerous professional demands, especially in academic settings. The belief that saying "yes" to everything is beneficial is misleading and can ...

HIFU minimizes adverse effects on urinary and sexual function, appealing to patients seeking less invasive prostate cancer treatments. Ideal candidates for HIFU are those with intermediate-risk, ...

"The durability response for these patients was impressive given the fact that these patients were those who, by definition and by inclusion criteria, were recurrent within a year at [baseline]," says ...

Management of mCSPC involves ADT combined with systemic therapies like docetaxel, abiraterone, enzalutamide, or apalutamide. These combination therapies improve overall survival and progression-free ...

The program offers comprehensive insights, reducing patient reliance on potentially misleading online information and extreme outcome comparisons. Encouraging healthcare providers to adopt this ...

The PRESERVE trial evaluates Irreversible Electroporation for prostate tissue ablation, seeking a specific indication for prostate cancer treatment. Irreversible Electroporation is already ...